Investor Presentaiton
CASHFLOW AND CASH CONVERSION
Strong free cash flow
AUD $m
(10.4)
Free cash flow conversion of 96.8% (1H FY22
63.6%), after replacement capex
Growth capital expenditure was $5.1m in 1H
FY23
Changes in working capital excludes
accruals for non-operating transaction
costs and capex as well as working capital
acquired on 1 July 2022 as part of the
Peloton Radiology and Horizon Radiology
acquisitions
1H FY23
1H FY22⚫
Operating EBITDA
39.8
38.8
Non-cash items in EBITDA
(0.2)
0.2
Changes in working capital
16.9
(2.8)
Replacement capital
expenditure
(8.5)
(4.2)
Cash payments on leases
(9.5)
(7.2)
Free cash flow
38.5
24.7
Growth capital expenditure
(5.1)
Net cash flow before
financing, acquisitions and
taxation
33.4
14.3
Free cash flow conversion,
96.8%
63.6%
after replacement capex
idxView entire presentation